Short Interest in Immatics (NASDAQ:IMTXW) Grows By 14.3%

Immatics (NASDAQ:IMTXWGet Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,600 shares, a growth of 14.3% from the February 29th total of 1,400 shares. Based on an average trading volume of 4,100 shares, the days-to-cover ratio is presently 0.4 days.

Immatics Price Performance

Immatics stock opened at $2.96 on Tuesday. The company’s 50 day simple moving average is $3.43 and its 200 day simple moving average is $3.01. Immatics has a fifty-two week low of $1.20 and a fifty-two week high of $4.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMTXW. Virtu Financial LLC bought a new position in Immatics in the fourth quarter valued at approximately $28,000. Jefferies Financial Group Inc. bought a new position in Immatics in the fourth quarter valued at approximately $80,000. Alyeska Investment Group L.P. bought a new position in Immatics in the fourth quarter valued at approximately $529,000. Walleye Capital LLC lifted its stake in Immatics by 25.7% in the second quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock valued at $889,000 after buying an additional 53,153 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Immatics by 11.9% in the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock valued at $1,293,000 after buying an additional 40,168 shares in the last quarter.

Immatics Company Profile

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Recommended Stories

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.